2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycythemia Vera
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Carcinoma, Hepatocellular
6
Thrombocythemia, Essential
5
Neoplasms
3
Melanoma
3
Skin Neoplasms
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Leukemia
2
Hepatitis C, Chronic
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Solid Cancers
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Neoplasm of Uncertain Malignant Potential
1
Liver Cirrhosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Influenza, Human
1
Infections
1
Hepatitis D
1
Hepatitis C
1
Hepatitis B, Chronic
1
Hepatitis B
1
Hemangiosarcoma
1
Interventions
entecavir
10
Lamivudine
5
Tenofovir
4
lenvatinib
2
Sorafenib
2
Radiofrequency Ablation
2
Hepatitis B Vaccines
2
tenofovir alafenamide
1
polysaccharide MGN3
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
navitoclax
1
menatetrenone
1
lens intermediate filament proteins
1
human papillomavirus vaccine, L1 type 16, 18
1
hepatitis B hyperimmune globulin
1
bicyclol
1
adefovir dipivoxil
1
adefovir
1
Urinalysis
1
Ultrasonography
1
Tumor Necrosis Factor-alpha
1
Tetanus Toxoid
1
Telbivudine
1
Tablets
1
Standard of Care
1
Rapid Diagnostic Tests
1
Raltegravir Potassium
1
Radiomics
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatitis B
×
peginterferon alfa-2a
×
Clear all
NCT05683548
2025-02-17
RCAP
Replicor Inc.
No longer available